These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2949253)

  • 61. COVID-19 challenges and its therapeutics.
    Rehman SU; Rehman SU; Yoo HH
    Biomed Pharmacother; 2021 Oct; 142():112015. PubMed ID: 34388532
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.
    Heustess AM; Allard MA; Thompson DK; Fasinu PS
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34071185
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.
    Aviani JK; Halim D; Soeroto AY; Achmad TH; Djuwantono T
    Rev Med Virol; 2021 Nov; 31(6):e2225. PubMed ID: 33621405
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19.
    Ripoll JG; van Helmond N; Senefeld JW; Wiggins CC; Klassen SA; Baker SE; Larson KF; Murphy BM; Andersen KJ; Ford SK; Casadevall A; Joyner MJ
    Clin Microbiol Newsl; 2021 Feb; 43(4):23-32. PubMed ID: 33564204
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A look-back at convalescent plasma to treat COVID-19.
    Garraud O; Lacombe K; Tiberghien P
    Transfus Apher Sci; 2021 Feb; 60(1):103063. PubMed ID: 33478889
    [No Abstract]   [Full Text] [Related]  

  • 66. A novel circulating tamiami mammarenavirus shows potential for zoonotic spillover.
    Moreno H; Rastrojo A; Pryce R; Fedeli C; Zimmer G; Bowden TA; Gerold G; Kunz S
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0009004. PubMed ID: 33370288
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Elucidating the pivotal role of convalescent plasma therapy in critically ill COVID-19 patients: A review.
    Richard SA; Kampo S; Esquijarosa Hechavarria M
    Hematol Rep; 2020 Dec; 12(3):8630. PubMed ID: 33324480
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma.
    Maor Y; Cohen D; Paran N; Israely T; Ezra V; Axelrod O; Shinar E; Izak M; Rahav G; Rahimi-Levene N; Bazofin BM; Gelman R; Dicker D; Brosh-Nissimov T; Megged O; Dahan D; Benov A; Paz A; Edward K; Moran A; Rogowski O; Sorkine P; Mayo A; Zimhony O; Chen J
    EClinicalMedicine; 2020 Sep; 26():100525. PubMed ID: 32923991
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19.
    Pourahmad R; Moazzami B; Rezaei N
    SN Compr Clin Med; 2020; 2(9):1407-1411. PubMed ID: 32838178
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunoglobulin fragment F(ab')
    Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
    Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic.
    Sullivan HC; Roback JD
    Transfus Med Rev; 2020 Jul; 34(3):145-150. PubMed ID: 32359788
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Convalescent plasma: possible therapy for novel coronavirus disease 2019.
    Cao H; Shi Y
    Transfusion; 2020 May; 60(5):1078-1083. PubMed ID: 32359090
    [No Abstract]   [Full Text] [Related]  

  • 73. Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus.
    Pan X; Wu Y; Wang W; Zhang L; Xiao G
    Antiviral Res; 2020 Feb; 174():104666. PubMed ID: 31760108
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Review of
    Hallam SJ; Koma T; Maruyama J; Paessler S
    Front Microbiol; 2018; 9():1751. PubMed ID: 30123198
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Native functionality and therapeutic targeting of arenaviral glycoproteins.
    Crispin M; Zeltina A; Zitzmann N; Bowden TA
    Curr Opin Virol; 2016 Jun; 18():70-5. PubMed ID: 27104809
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Convalescent plasma: new evidence for an old therapeutic tool?
    Marano G; Vaglio S; Pupella S; Facco G; Catalano L; Liumbruno GM; Grazzini G
    Blood Transfus; 2016 Mar; 14(2):152-7. PubMed ID: 26674811
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses.
    Mahmutovic S; Clark L; Levis SC; Briggiler AM; Enria DA; Harrison SC; Abraham J
    Cell Host Microbe; 2015 Dec; 18(6):705-13. PubMed ID: 26651946
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reactive astrogliosis in response to hemorrhagic fever virus: microarray profile of Junin virus-infected human astrocytes.
    Kolokoltsova OA; Yun NE; Paessler S
    Virol J; 2014 Jul; 11():126. PubMed ID: 25015256
    [TBL] [Abstract][Full Text] [Related]  

  • 79. RIG-I enhanced interferon independent apoptosis upon Junin virus infection.
    Kolokoltsova OA; Grant AM; Huang C; Smith JK; Poussard AL; Tian B; Brasier AR; Peters CJ; Tseng CT; de la Torre JC; Paessler S
    PLoS One; 2014; 9(6):e99610. PubMed ID: 24918927
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Junín virus pathogenesis and virus replication.
    Grant A; Seregin A; Huang C; Kolokoltsova O; Brasier A; Peters C; Paessler S
    Viruses; 2012 Oct; 4(10):2317-39. PubMed ID: 23202466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.